Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

Bibliography

• Mayeux R, Stern Y. Epidemiology of alzheimer disease. Cold Spring Harb Perspect Med 2012;2(8):1-18
   Google Scholar
• Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479-86
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological staging of alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
   PubMed Web of Science ®Google Scholar
• Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115(6):1449-57
   PubMed Web of Science ®Google Scholar
• Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis–lessons from amyloid precursor protein processing. J Neurochem 2011;117(5):779-96
   PubMed Web of Science ®Google Scholar
• St George-Hyslop P, Fraser PE. Assembly of the presenilin gamma-/epsilon-secretase complex. J Neurochem 2012;120(Suppl 1):84-8
   PubMedGoogle Scholar
• Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's abeta peptide: the many roads to perdition. Neuron 2004;43(5):605-8
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000;924:17-25
   PubMed Web of Science ®Google Scholar
• Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 2011;108(14):5819-24
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261(5123):921-3
   PubMed Web of Science ®Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467-72
   PubMed Web of Science ®Google Scholar
• Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39(1):17-23
   PubMed Web of Science ®Google Scholar
• Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A meta-analysis. APOE and alzheimer disease meta analysis consortium. JAMA 1997;278(16):1349-56
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nat Genet 1994;7(2):180-4
   PubMed Web of Science ®Google Scholar
• Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343(8910):1432-3
   PubMedGoogle Scholar
• Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14(1):55-61
   PubMed Web of Science ®Google Scholar
• Sen A, Alkon DL, Nelson TJ. Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J Biol Chem 2012;287(19):15947-58
   PubMedGoogle Scholar
• Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 2012;32(43):15181-92
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008;118(12):4002-13
   PubMed Web of Science ®Google Scholar
• Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007;27(5):909-18
   PubMed Web of Science ®Google Scholar
• Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006;7(11):850-9
   PubMed Web of Science ®Google Scholar
• May P, Herz J. LDL receptor-related proteins in neurodevelopment. Traffic 2003;4(5):291-301
   PubMed Web of Science ®Google Scholar
• Cam JA, Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 2006;1:8
   PubMed Web of Science ®Google Scholar
• Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 2012;85(1):19-28
   PubMedGoogle Scholar
• Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003;5(1):1-8
   PubMedGoogle Scholar
• Holtzman DM, Herz J, Bu G. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in alzheimer disease. Cold Spring Harb Perspect Med 2012;2(3):a006312
   PubMed Web of Science ®Google Scholar
• Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008;88(3):887-918
   PubMed Web of Science ®Google Scholar
• Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10(5):333-44
   PubMed Web of Science ®Google Scholar
• Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 2001;108(6):779-84
   PubMed Web of Science ®Google Scholar
• Boucher P, Herz J. Signaling through LRP1: protection from atherosclerosis and beyond. Biochem Pharmacol 2011;81(1):1-5
   PubMed Web of Science ®Google Scholar
• Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-golgi compartment. EMBO J 1990;9(6):1769-76
   PubMedGoogle Scholar
• Willnow TE, Moehring JM, Inocencio NM, et al. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Biochem J 1996;313(Pt 1):71-6
   PubMedGoogle Scholar
• Croy JE, Shin WD, Knauer MF, et al. All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands. Biochemistry 2003;42(44):13049-57
   PubMedGoogle Scholar
• Obermoeller-McCormick LM, Li Y, Osaka H, et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 2001;114(Pt 5):899-908
   PubMedGoogle Scholar
• Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106(12):1489-99
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011;12(12):723-38
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 2000;6(7):718-19
   Web of Science ®Google Scholar
• Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330(6012):1774
   PubMed Web of Science ®Google Scholar
• Gylys KH, Fein JA, Tan AM, Cole GM. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem 2003;84(6):1442-51
   PubMedGoogle Scholar
• Fuentealba RA, Liu Q, Zhang J, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 2010;5(7):e11884
   Google Scholar
• Zerbinatti CV, Wahrle SE, Kim H, et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 2006;281(47):36180-6
   PubMedGoogle Scholar
• Hu X, Crick SL, Bu G, et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 2009;106(48):20324-9
   PubMed Web of Science ®Google Scholar
• Ji ZS, Mullendorff K, Cheng IH, et al. Reactivity of apolipoprotein E4 and amyloid beta peptide: Lysosomal stability and neurodegeneration. J Biol Chem 2006;281(5):2683-92
   PubMedGoogle Scholar
• Ji ZS, Miranda RD, Newhouse YM, et al. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem 2002;277(24):21821-8
   PubMed Web of Science ®Google Scholar
• Belinson H, Lev D, Masliah E, Michaelson DM. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci 2008;28(18):4690-701
   PubMedGoogle Scholar
• Li J, Kanekiyo T, Shinohara M, et al. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 2012;287(53):44593-601
   PubMed Web of Science ®Google Scholar
• Kanekiyo T, Liu CC, Shinohara M, et al. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-beta. J Neurosci 2012;32(46):16458-65
   PubMedGoogle Scholar
• Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18(2):253-66
   PubMedGoogle Scholar
• Wilhelmus MM, Otte-Holler I, van Triel JJ, et al. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 2007;171(6):1989-99
   PubMedGoogle Scholar
• Ruzali WA, Kehoe PG, Love S. Influence of LRP-1 and apolipoprotein E on amyloid-beta uptake and toxicity to cerebrovascular smooth muscle cells. J Alzheimers Dis 2013;33(1):95-110
   PubMedGoogle Scholar
• Ruzali WA, Kehoe PG, Love S. LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status. Neurosci Lett 2012;525(2):123-8
   PubMedGoogle Scholar
• Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004;10(7):719-26
   PubMed Web of Science ®Google Scholar
• Carlo AS, Gustafsen C, Mastrobuoni G, et al. The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain. J Neurosci 2013;33(1):358-70
   PubMedGoogle Scholar
• Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of abeta isoforms. Neuron 2004;43(3):333-44
   PubMed Web of Science ®Google Scholar
• Daneman R. The blood-brain barrier in health and disease. Ann Neurol 2012;72(5):648-72
   PubMed Web of Science ®Google Scholar
• Shiiki T, Ohtsuki S, Kurihara A, et al. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 2004;24(43):9632-7
   PubMedGoogle Scholar
• Pflanzner T, Janko MC, Andre-Dohmen B, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 2011;32(12):2323; e1,2323.11
   PubMedGoogle Scholar
• Sagare AP, Deane R, Zlokovic BV. Low-density lipoprotein receptor-related protein 1: a physiological abeta homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther 2012;136(1):94-105
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Deane R, Sagare AP, et al. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem 2010;115(5):1077-89
   PubMed Web of Science ®Google Scholar
• Bachmeier C, Paris D, Beaulieu-Abdelahad D, et al. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis 2013;11(1):13-21
   PubMedGoogle Scholar
• Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem 2001;276(21):18000-6
   PubMedGoogle Scholar
• Urich E, Lazic SE, Molnos J, et al. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 2012;7(5):e38149
   Google Scholar
• Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994;63:601-37
   PubMed Web of Science ®Google Scholar
• Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 2006;56(3):246-52
   PubMed Web of Science ®Google Scholar
• Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 2010;113(5):1356-63
   PubMedGoogle Scholar
• Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 2008;30(1):94-102
   PubMedGoogle Scholar
• Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an alzheimer disease mouse model. J Clin Invest 2005;115(11):3285-90
   PubMed Web of Science ®Google Scholar
• Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010;77(5):715-23
   PubMedGoogle Scholar
• Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996;93(9):4229-34
   PubMed Web of Science ®Google Scholar
• Carro E, Spuch C, Trejo JL, et al. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 2005;25(47):10884-93
   PubMedGoogle Scholar
• Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010;22(3):849-59
   PubMedGoogle Scholar
• Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9(7):907-13
   PubMed Web of Science ®Google Scholar
• von Arnim CA, Kinoshita A, Peltan ID, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 2005;280(18):17777-85
   PubMedGoogle Scholar
• Liu Q, Zhang J, Tran H, et al. LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 2009;4:17; 1326-4-17
   PubMedGoogle Scholar
• Liang F, Jia J, Wang S, et al. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J Clin Neurosci 2012;20:3):357-61
   PubMedGoogle Scholar
• Quinn KA, Grimsley PG, Dai YP, et al. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 1997;272(38):23946-51
   PubMed Web of Science ®Google Scholar
• Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007;13(9):1029-31
   PubMedGoogle Scholar
• Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier abeta clearance in Alzheimer's disease. Curr Pharm Des 2008;14(16):1601-5
   PubMed Web of Science ®Google Scholar
• Charlton MR. Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab 1996;10(4):617-35
   PubMedGoogle Scholar
• Ghiso J, Shayo M, Calero M, et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 2004;279(44):45897-908
   PubMed Web of Science ®Google Scholar
• Tamaki C, Ohtsuki S, Iwatsubo T, et al. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 2006;23(7):1407-16
   PubMedGoogle Scholar
• Mackic JB, Bading J, Ghiso J, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 2002;38(6):303-13
   PubMedGoogle Scholar
• Mackic JB, Weiss MH, Miao W, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70(1):210-15
   PubMedGoogle Scholar
• Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 2007;72(4):850-5
   PubMedGoogle Scholar
• Smith CC, Betteridge DJ. Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 2004;367(1):48-50
   PubMedGoogle Scholar
• Sharman MJ, Morici M, Hone E, et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 2010;21(2):403-9
   PubMed Web of Science ®Google Scholar
• Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007;2:22
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286(5440):735-41
   PubMed Web of Science ®Google Scholar
• Parvathy S, Hussain I, Karran EH, et al. Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. Biochemistry 1999;38(30):9728-34
   PubMedGoogle Scholar
• Pasternak SH, Bagshaw RD, Guiral M, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem 2003;278(29):26687-94
   PubMed Web of Science ®Google Scholar
• Ray WJ, Yao M, Mumm J, et al. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of notch. J Biol Chem 1999;274(51):36801-7
   PubMedGoogle Scholar
• Rechards M, Xia W, Oorschot VM, et al. Presenilin-1 exists in both pre- and post-golgi compartments and recycles via COPI-coated membranes. Traffic 2003;4(8):553-65
   PubMedGoogle Scholar
• Annaert WG, Levesque L, Craessaerts K, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol 1999;147(2):277-94
   PubMed Web of Science ®Google Scholar
• Cam JA, Zerbinatti CV, Li Y, Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J Biol Chem 2005;280(15):15464-70
   PubMedGoogle Scholar
• Ulery PG, Beers J, Mikhailenko I, et al. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 2000;275(10):7410-15
   PubMed Web of Science ®Google Scholar
• Zerbinatti CV, Wozniak DF, Cirrito J, et al. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 2004;101(4):1075-80
   PubMedGoogle Scholar
• Knauer MF, Orlando RA, Glabe CG. Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). Brain Res 1996;740(1-2):6-14
   PubMedGoogle Scholar
• Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82(2):331-40
   PubMed Web of Science ®Google Scholar
• Pietrzik CU, Busse T, Merriam DE, et al. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 2002;21(21):5691-700
   PubMedGoogle Scholar
• Pietrzik CU, Yoon IS, Jaeger S, et al. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 2004;24(17):4259-65
   PubMedGoogle Scholar
• Rebeck GW, Moir RD, Mui S, et al. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res Mol Brain Res 2001;87(2):238-45
   PubMedGoogle Scholar
• Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 1998;273(50):33556-60
   PubMedGoogle Scholar
• Klug W, Dietl A, Simon B, et al. Phosphorylation of LRP1 regulates the interaction with Fe65. FEBS Lett 2011;585(20):3229-35
   PubMedGoogle Scholar
• Ando K, Iijima KI, Elliott JI, et al. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem 2001;276(43):40353-61
   PubMed Web of Science ®Google Scholar
• Tanahashi H, Tabira T. Molecular cloning of human Fe65L2 and its interaction with the Alzheimer's beta-amyloid precursor protein. Neurosci Lett 1999;261(3):143-6
   PubMedGoogle Scholar
• Sabo SL, Lanier LM, Ikin AF, et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem 1999;274(12):7952-7
   PubMedGoogle Scholar
• Santiard-Baron D, Langui D, Delehedde M, et al. Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load. J Neurochem 2005;93(2):330-8
   PubMedGoogle Scholar
• Wahler A, Beyer AS, Keller IE, et al. Engulfment adapter PTB domain containing 1 (GULP1) is a nucleocytoplasmic shuttling protein and transactivationally active together with low density lipoprotein receptor-related protein 1 (LRP1). Biochem J 2013;450(2):333-43
   PubMedGoogle Scholar
• Alvira-Botero X, Perez-Gonzalez R, Spuch C, et al. Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Mol Cell Neurosci 2010;45(3):306-15
   PubMedGoogle Scholar
• Lakshmana MK, Chen E, Yoon IS, Kang DE. C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. J Cell Mol Med 2008;12(6B):2665-74
   PubMedGoogle Scholar
• Lakshmana MK, Yoon IS, Chen E, et al. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J Biol Chem 2009;284(18):11863-72
   PubMedGoogle Scholar
• Lakshmana MK, Hayes CD, Bennett SP, et al. Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J 2012 May;26(5):2072-83
   PubMedGoogle Scholar
• Lakshmana MK, Chung JY, Wickramarachchi S, et al. A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J 2010;24(1):119-27
   PubMedGoogle Scholar
• Ye S, Huang Y, Mullendorff K, et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005;102(51):18700-5
   PubMed Web of Science ®Google Scholar
• Biere AL, Ostaszewski B, Zhao H, et al. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol Dis 1995;2(3):177-87
   PubMedGoogle Scholar
• Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006;112(4):405-15
   PubMed Web of Science ®Google Scholar
• Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000;106(9):1159-66
   PubMed Web of Science ®Google Scholar
• Moon JH, Kang SB, Park JS, et al. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor atorvastatin and hepatic LRP1 expression. Metabolism 2011;60(7):930-40
   PubMedGoogle Scholar
• Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35(11 Suppl 1):2628-31
   PubMed Web of Science ®Google Scholar
• Shinohara M, Sato N, Kurinami H, et al. Reduction of brain beta-amyloid (abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and abeta clearance. J Biol Chem 2010;285(29):22091-102
   PubMed Web of Science ®Google Scholar
• Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 2012; Epub ahead of print
   Google Scholar
• Sehgal N, Gupta A, Valli RK, et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 2012;109(9):3510-15
   PubMed Web of Science ®Google Scholar
• Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 2012;31(1):151-65
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-9
   PubMed Web of Science ®Google Scholar
• Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging 2009;30(3):337-52
   PubMed Web of Science ®Google Scholar
• Sagare AP, Deane R, Zetterberg H, et al. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 2011;24(1):25-34
   PubMedGoogle Scholar
• Sutcliffe JG, Hedlund PB, Thomas EA, et al. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011;89(6):808-14
   PubMedGoogle Scholar